Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Extending dual GIP [glucose-dependent insulinotropic polypeptide]/GLP1 [glucagon-like peptide-1] receptor agonist therapy to this population introduces a treatment that addresses both glycaemic control and obesity-related risk, she added
This helps reduce swelling by preventing fluid from pooling in the treated areas
[4] If you have a CGM (or even a simple fasting-glucose finger-stick monitor), tracking these markers gives you a vastly clearer picture of whether the medication is working than waiting for the scale to move
They remain prescription therapeutics used under physician discretion
Available from: Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
